Nanjing Leads Biolabs (HKG:9887) said the stabilization period of its Hong Kong listing ended on Thursday, Aug. 21, according to a same-day Hong Kong bourse filing.

Shares of the company closed 4% lower on Friday.

The IPO's stabilizing manager overallocated 12,821,700 H shares in the international portion of the offering, while underwriters fully exercised their overallotment option to purchase 5,529,300 shares.

No H shares were sold or purchased on the market during the stabilization period, the company said.

The biotech company said its public float continues to comply with Hong Kong's listing requirements.